Three Doses of Pfizer-BioNTech COVID-19 Vaccine is Efficacious in Young Children

Article

Administered during the Omicron-dominant phase, the vaccine's efficacy was 73.2% in individuals 6 months to 4 years of age.

A three-dose primary series of 3-μg BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine was found to be safe, immunogenic, and efficacious in children 6 months to 4 years of age, according to a new study.

The study’s results were published in The New England Journal of Medicine.

Overall, a vaccine efficacy of 73.2% was observed in individuals 6 months to 4 years of age. In children ages 6 months to less than 2 years of age, the vaccine demonstrated a 75.8% efficacy, and among children 2 to 4 years of age it was 71.8% efficacious.

In the phase 2–3 trial, participants were randomly assigned (in a 2:1 ratio) to receive two 3-μg doses of BNT162b2 or placebo. The participants included 1178 children 6 months to less than 2 years of age, and 1835 children 2 to 4 years of age who received the Pfizer-BioNTech vaccine, and 598 and 915, respectively, received placebo.

The investigators administered two 3-μg BNT162b2 doses 21 days apart followed by a third dose given at least 8 weeks later.

“On the basis of preliminary immunogenicity results, a third 3-μg dose (≥8 weeks after dose 2) was administered starting in January 2022, which coincided with the emergence of the B.1.1.529 (Omicron) variant,” the investigators wrote. “Immune responses at 1 month after doses 2 and 3 in children 6 months to less than 2 years of age and those 2 to 4 years of age were immunologically bridged to responses after dose 2 in persons 16 to 25 years of age who received 30 μg of BNT162b2 in the pivotal trial.”

The vaccines were reported to be safe and immunogenic in children 6 months to 4 years of age.

“Immunobridging success criteria for the geometric mean ratio and seroresponse at 1 month after dose 3 were met in both age groups. BNT162b2 reactogenicity events were mostly mild to moderate, with no grade 4 events. Low, similar incidences of fever were reported after receipt of BNT162b2 (7% among children 6 months to <2 years of age and 5% among those 2 to 4 years of age) and placebo (6 to 7% among children 6 months to <2 years of age and 4 to 5% among those 2 to 4 years of age),” the investigators wrote.

The investigators said limitations included that the study did not assess efficacy against severe disease or against specific SARS-CoV-2 variants. The investigators lacked data on Omicron BA4 and BA5 serum-neutralizing activity and longer-term follow-up to assess immune-response duration as well as safety. In addition, the trial population was predominantly White participants.

“These data support vaccination of children 6 months to 4 years of age with three 3-μg primary BNT162b2 doses,” the authors concluded.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.